Skip to content
November 26, 2022

Equity.Guru

Investment information for the new generation

MMED.E

We’re living in interesting times and I mean that in the Chinese curse kind of way. We can’t seem to stop to catch our breath when it comes to…
This week, news from the psychedelic sector has been dominated by patent applications and earnings being released. Here’s the run down of this week’s news. Cybin (CYBN.NE) It’s been…
MindMed (MMED.NE, MNMD.Q) announced the start of a Phase 1 trial to assess the safety, pharmacokinetics and pharmacodynamics of DMT. DMT, properly known as N,N-Dimethyltryptamine is a psychoactive chemical…
Mind Medicine (MMED.NE, MNMD.Q) announced that J.R. Rahn is stepping down from his roles as CEO and director. Rahn was a co-founder of the company and was at the…
Mind Medicine (MMED.NE) announced the publication of the first pharmacogenetic data on LSD to help personalize dosing. The study results from a pooled secondary analysis of four Phase I…
The notion of magic mushroom market offering after the legalization of cannabis has been floated time and again since long before cannabis legalization was even on the table. It…
Shroom BOOM! MindMed has been one of the talk on the street, with price jumping over 50% this month and market cap exceeding 1 Billion! Shroom stocks have been…
Mind Medicine (MMED.E) closed a bought deal short-form prospectus offering, issuing 27,381,500 units for $1.05 and brought in $28,750,575 today, according to a press release. After the financing, the…
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./ NEW YORK, Oct. 9, 2020 /CNW/ – Mind…
Mind Medicine (MMED.E) is raising money to found and launch a clinical training program focused on developing psychedelic-assisted therapies and medicines at New York University’s (NYU) Langone Health. The…